相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group
Vasiliki Nikolaou et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events
Linda Chan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
The life-threatening eruptions of immune checkpoint inhibitor therapy
Emily L. Coleman et al.
CLINICS IN DERMATOLOGY (2020)
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
Samantha R. Ellis et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Immune checkpoint inhibitor-related dermatologic adverse events
Amaris N. Geisler et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
Naoko Okura et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy
Anna J. Lomax et al.
INTERNAL MEDICINE JOURNAL (2019)
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Emily Coleman et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab
B. Page et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Two cases of granuloma annulare under anti-PD1 therapy
R. Charollais et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Jacob Siegel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
Leo L. Wang et al.
JAMA DERMATOLOGY (2018)
Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy
Vincent Sibaud
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Laura C. Cappelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Jonathan L. Curry et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2017)
Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma
Raul E. Perret et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2017)
Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy
Karina L. Vivar et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Cutaneous adverse effects of the immune checkpoint inhibitors
Lindsey K. Collins et al.
CURRENT PROBLEMS IN CANCER (2017)
Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features
Michael T. Tetzlaff et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2017)
Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma
Y. Kato et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma
Natsuko Matsumura et al.
ACTA DERMATO-VENEREOLOGICA (2016)
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Vincent Sibaud et al.
CURRENT OPINION IN ONCOLOGY (2016)
Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
Kurt B. Schaberg et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2016)
Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma
Shelley J. E. Hwang et al.
MELANOMA RESEARCH (2016)
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy
Veronica J. Shi et al.
JAMA DERMATOLOGY (2016)
Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
Viktor H. Koelzer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
Marc Uemura et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
A case of drug-associated dermatomyositis following ipilimumab therapy
Yasuyuki Yamaguchi et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2016)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
First report of ipilimumab-induced Grover disease
J. Munoz et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma
K Sanderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
